Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Theodore Prentice

Neurology Santa Monica, CA Medical Doctor

NPI 1194733436 CMS profile 99591

2730 Wilshire Blvd 620, Santa Monica, CA 90403

Open in the dashboard

General payments

$9,006

570 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Theodore Prentice of Santa Monica, CA is reported in the CMS Open Payments database as having received $9,006 across 570 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $57 2
2022 General $1,120 85
2021 General $2,563 165
2020 General $1,780 132
2019 General $3,486 186

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Prentice
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Theodore Prentice were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Theodore Prentice Neurology median Middle half National median
2019 $3,486 $474 $118–$2,177 $163
2020 $1,780 $367 $82–$2,309 $114
2021 $2,563 $438 $104–$2,547 $132
2022 $1,120 $442 $103–$2,388 $149
2023 $57 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. UCB, Inc. $966 86 payments
  2. Teva Pharmaceuticals USA, Inc. $921 69 payments
  3. Sunovion Pharmaceuticals Inc. $792 57 payments
  4. Supernus Pharmaceuticals, Inc. $678 6 payments
  5. Novartis Pharmaceuticals Corporation $550 22 payments
  6. Neurocrine Biosciences, Inc. $470 31 payments
  7. Biogen, Inc. $456 18 payments
  8. SK Life Science, Inc. $401 25 payments
  9. AbbVie, Inc. $379 30 payments
  10. LivaNova USA, Inc. $359 45 payments
  11. Other $3,034 181 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,016 554 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $671 10 payments
  3. Education $318 6 payments
Products named General payments · program years 2019–2023
  1. OXTELLAR XR $654 4 payments
  2. Briviact $603 56 payments
  3. APTIOM $555 41 payments
  4. AUSTEDO $501 45 payments
  5. Vimpat $332 27 payments
  6. NUPLAZID $332 28 payments
  7. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $328 43 payments
  8. INGREZZA $310 22 payments
  9. RYTARY $295 6 payments
  10. AIMOVIG $269 9 payments
  11. Other $4,339 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

570 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record